Page last updated: 2024-12-10

kallidin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Kallidin: A decapeptide bradykinin homolog cleaved from kininogen by kallikreins. It is a smooth-muscle stimulant and hypotensive agent that acts by vasodilatation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311111
CHEBI ID6102
SCHEMBL ID150645
MeSH IDM0011893

Synonyms (24)

Synonym
gtpl650
lys-bk
[lys]bradykinin
kallidin ii
342-10-9
C01505
lysyl-bradykinin
lysylbradykinin
kallidin
einecs 206-438-0
lys-bradykinin
bradykinin, n2-l-lysyl-
2-[[2-[[1-[2-[[2-[[2-[[1-[1-[2-(2,6-diaminohexanoylamino)-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]am
(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyr
0t8t4a440g ,
unii-0t8t4a440g
SCHEMBL150645
AKOS024457492
CHEBI:6102
(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-5-guanidino-pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenyl-propanoyl]amino]-3-hydroxy-propanoyl]pyrrolidine-2-ca
DTXSID40895018
Q2398786
CS-0027229
HY-103293

Research Excerpts

Overview

Kallidin (KD) is an important vasoactive kinin whose physiological effects are strongly dependent on its degradation through local kininases.

ExcerptReferenceRelevance
"Kallidin (KD) is an important vasoactive kinin whose physiological effects are strongly dependent on its degradation through local kininases. "( Identification of kallidin degrading enzymes in the isolated perfused rat heart.
Dendorfer, A; Dominiak, P; Wolfrum, S, 1999
)
2.08

Bioavailability

ExcerptReferenceRelevance
" ELN441958 is a novel small molecule bradykinin B(1) receptor antagonist exhibiting high oral bioavailability and potent systemic efficacy in rhesus monkey inflammatory pain."( Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.
Bova, MP; Butelman, ER; Chavez, RA; Chen, L; Dreyer, M; Fukuda, JY; Garofalo, AW; Hawkinson, JE; Holcomb, R; Hom, DS; Ko, MC; Liao, A; Malmberg, AB; Ruslim, L; Samant, B; Simmonds, S; Szoke, BG; Wadsworth, A; Zeitz, KP; Zhang, H; Zmolek, W, 2007
)
0.34

Dosage Studied

We have examined the time-course of the inflammatory (weal and flare) responses to intradermal kallidin (lysbradykinin) in normal volunteers and patients with psoriasis. Hoe 140, dose-dependently shifted the dose-response curves of bradykinins to the right. Des-Arg10-[Leu9]-kallidIn proved ineffective.

ExcerptRelevanceReference
" The dose-response curves of bradykinin."( A sensitive radioimmunoassay method for urinary kinins in man.
Ando, T; Miyahara, M; Nakao, T; Sakuma, M; Shimamoto, K; Tanaka, S, 1978
)
0.26
" In both preparations, B4310 caused a parallel shift of the dose-response curves to BK."( Functional analysis of kinin antagonists.
Griesbacher, T; Lembeck, F, 1990
)
0.28
"5-2 mg/ml) caused a parallel and concentration-dependent rightward displacement to all three kinins dose-response curves."( Antagonistic effect of Mandevilla velutina extract on kinin-induced contractions of guinea-pig and cat ileum longitudinal smooth muscle.
Calixto, JB; Nicolau, M; Yunes, RA, 1988
)
0.27
" We have examined the time-course of the inflammatory (weal and flare) responses to intradermal kallidin (lysbradykinin) and bradykinin in normal volunteers, and have compared the dose-response effect of these agents in normal volunteers and patients with psoriasis."( Comparison of the actions of kallidin and bradykinin in the skin of normal and psoriatic subjects.
Archer, CB; Burton, JL; Marshman, G, 1996
)
0.8
" Hoe 140, dose-dependently shifted the dose-response curves of bradykinin to the right, whereas the bradykinin B1 receptor antagonist, des-Arg10-[Leu9]-kallidin proved ineffective."( Positive chronotropic activity of bradykinin in the pithed normotensive rat.
Loro, JF; Pfaffendorf, M; van Zwieten, PA; Zhang, J, 1998
)
0.5
" However, when animals were pre-treated with BCG, the dose-response curves for both B1 agonists were shifted 2 to 8-fold to the left."( Systemic treatment with Mycobacterium bovis bacillus Calmette-Guérin (BCG) potentiates kinin B1 receptor agonist-induced nociception and oedema formation in the formalin test in mice.
Calixto, JB; de Campos, RO; Henriques, MG, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1346532Mouse B1 receptor (Bradykinin receptors)1996Immunopharmacology, Jun, Volume: 33, Issue:1-3
The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors.
AID1346532Mouse B1 receptor (Bradykinin receptors)1994Molecular pharmacology, Jan, Volume: 45, Issue:1
Differential pharmacology of cloned human and mouse B2 bradykinin receptors.
AID1346495Human B1 receptor (Bradykinin receptors)1999European journal of pharmacology, Jun-25, Volume: 374, Issue:3
Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
AID1346495Human B1 receptor (Bradykinin receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization.
AID1346530Rat B1 receptor (Bradykinin receptors)1999European journal of pharmacology, Jun-25, Volume: 374, Issue:3
Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
AID1346510Mouse B2 receptor (Bradykinin receptors)1994Molecular pharmacology, Jan, Volume: 45, Issue:1
Differential pharmacology of cloned human and mouse B2 bradykinin receptors.
AID1346473Human B2 receptor (Bradykinin receptors)1994Molecular pharmacology, Jan, Volume: 45, Issue:1
Differential pharmacology of cloned human and mouse B2 bradykinin receptors.
AID1346495Human B1 receptor (Bradykinin receptors)1997The Journal of biological chemistry, Apr-25, Volume: 272, Issue:17
Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (517)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990277 (53.58)18.7374
1990's135 (26.11)18.2507
2000's80 (15.47)29.6817
2010's23 (4.45)24.3611
2020's2 (0.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.25 (24.57)
Research Supply Index6.30 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (2.25%)5.53%
Reviews44 (8.24%)6.00%
Case Studies1 (0.19%)4.05%
Observational0 (0.00%)0.25%
Other477 (89.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]